Breathing Life Into Inhaled Antibiotics: US FDA Tries To Move Class Ahead After Two Rejections
Executive Summary
Workshop on inhaled antibiotics serves as unusual post mortem after two public rejections at advisory committee level; agency clearly eager not to see development in field end.
You may also be interested in...
Insmed’s Amikacin Faces US FDA Questions On Surrogate Endpoint, Target Population
Amikacin liposome inhalation suspension seeking accelerated approval to treat nontubercuolous mycobacterial lung disease caused by Mycobacterium avium complex in adults but has only studied patients with refractory disease; agency also wants its advisory committee to opine on confirmatory trial design.
Aradigm's Linhaliq Suffers 'No' For Reducing Time To Exacerbations At US FDA Panel
Discordant results on Phase III primary endpoint in non-cystic fibrosis bronchiectasis patients troubled advisory committee members, although some suggested they would be more open to approval based upon secondary endpoint data on reduction in exacerbation frequency.
Bronchiectasis Trials Should Be Longer, Focus On Exacerbation Frequency
Bayer's endpoint for Phase III trials of ciprofloxacin inhaler should have focused on frequency of, rather than delay in, exacerbations, US FDA advisory committee members say; Aradigm's pending NDA in non-cystic fibrosis bronchiectasis could be impacted recommendations on endpoints, trial duration and concerns about long-term development of antibiotic resistance.